Areas of expertise
Unprecedented level of insight
Using our best-in-class biomarker discovery platform ScaiVisionTM, we can expose precise novel molecular signatures with single-cell insights.
End-to-end discovery process
We coordinate the entire biomarker development workflow end-to-end, from project design to an assay prototype.
Informing precision medicine
We identify and interpret the molecular patterns underlying complex diseases, which enables precise targeting of these mechanisms and tailor the therapeutic approach.
Best-in-class Plan
1.
Get in touch
Let’s discuss your specific focus, needs and requirements
2.
Project setup and data acquisition
We design together the appropriate biomarker discovery and/or assay development project. We coordinate the data acquisition process.
3.
Data analysis & result delivery
During the discovery stage of our work, we will provide you with a regular update on the progress and timelines.
Pharmaceutical companies
We enable pharmaceutical partners to study the drug mode of action on the single-cell level. We support the precision medicine approach by patient profiling. We increase the success rate of clinical trials and can detect molecular differences between responders and non-responders. We also build competence in the cell therapies manufacturing workflow and provide QC solutions on its various stages.
Diagnostic Companies
We help you develop new screening and stratification assays for the indications with high unmet clinical needs. Our ultra-sensitive biomarker signatures allow us to identify the patients and guide them to the most appropriate treatment.
Prof. Dr Michael Mueller
Leading Clinician in Women’s Health & Scientific Advisor
“Our current collaboration with Scailyte in the field of women’s health is a truly innovative approach. We are integrating cutting edge technologies to develop biomarkers that will be the basis for impactful diagnostic solutions.”
Pascal Koenig
Entrepreneur & Chairman of the Board of Directors
“As the co-founder and former CEO of Ava Women, I have experienced the power that big datasets have on the healthcare industry. Scailyte’s mission, proven technology and strong expertise have convinced me to join the team. I am delighted to contribute and assist in bringing Scailyte’s solution to patients around the world.”
Dominique Mégret
Scailyte Board of Directors & Head Swisscom Ventures
“Precision medicine is poised to become a standard in the future, however today it is facing a major obstacle: a data problem. The robust analytical engine of Scailyte makes it an enabler of precision medicine. We decided to support the company because we believe in the technology, as well as in the talented team behind it.”
Prof. Woong-Yang Park
Founder and CEO of Geninus
“Geninus aims to implement single-cell genome analysis techniques to facilitate personalized patient care. Scailyte’s machine learning model will add value to the single-cell
gene expression profile of patients. Through collaboration with Scailyte, we hope to provide prognostic methods for immunotherapy response in precision medicine clinics.”
Recent News
Single-Cell Discovery Grant in Oncology and Immunology
Open grant call of up to 100K Euro aimed at addressing unmet clinical needs in Oncology and Immunolo
Recent News
Scailyte and Lexogen create a joint biomarker discovery workflow for precision medicine companies
Scailyte, a single-cell biomarker discovery company and Lexogen, a leader in RNA sequencing solution
Recent News
Scailyte Quarterly Update, June 2021
Quarterly update on Scailyte's progress towards its mission to save millions of lives.
Recent News
Scailyte announces Michael Brenner, of Harvard Medical School, as an advisor to its Board of Directors
Artificial Intelligence (AI)-driven biomarker discovery innovator Scailyte announced today that Mich
Recent News
Recent News
Scailyte Quarterly Update, April 2021
Quarterly update on Scailyte's progress towards its mission to save millions of lives.
Recent News
Scailyte and Geninus announce a strategic partnership to develop a predictive assay for immune-checkpoint inhibitors in Non-Small Cell Lung Cancer patients
Artificial Intelligence (AI)-driven biomarker discovery innovator Scailyte and the global single-cel
Recent News
Scailyte and Volv Global announce strategic partnership to accelerate rare disease patient diagnosis
Two Artificial Intelligence (AI)-driven biomarker discovery companies Scailyte and Volv Global today
Recent News
Single-Cell Discovery Grant in Oncology and Immunology
Open grant call of up to 100K Euro aimed at addressing unmet clinical needs in Oncology and Immunolo
Scailyte and Lexogen create a joint biomarker discovery workflow for precision medicine companies
Scailyte, a single-cell biomarker discovery company and Lexogen, a leader in RNA sequencing solution
Recent News
Scailyte Quarterly Update, June 2021
Quarterly update on Scailyte's progress towards its mission to save millions of lives.
Scailyte announces Michael Brenner, of Harvard Medical School, as an advisor to its Board of Directors
Artificial Intelligence (AI)-driven biomarker discovery innovator Scailyte announced today that Mich
Recent News
Scailyte Quarterly Update, April 2021
Quarterly update on Scailyte's progress towards its mission to save millions of lives.
Recent News
Scailyte and Geninus announce a strategic partnership to develop a predictive assay for immune-checkpoint inhibitors in Non-Small Cell Lung Cancer patients
Artificial Intelligence (AI)-driven biomarker discovery innovator Scailyte and the global single-cel
Scailyte and Volv Global announce strategic partnership to accelerate rare disease patient diagnosis
Two Artificial Intelligence (AI)-driven biomarker discovery companies Scailyte and Volv Global today